The best explanation that we can offer to resolve our findings of STS expression being associated with beneficial survival outcomes across breast cancer subtypes, yet STS inhibition being beneficial as detailed above is similar to the explanation offered for the actions of oestrogen inhibition in ERα positive breast cancer or androgen inhibition in AR positive ERα negative breast cancer. The gene discussed is ESR1; the disease is breast carcinoma.